LARGO, Fla., Jan. 16 /PRNewswire-FirstCall/ -- GeoPharma, Inc. (NASDAQ:GORX) (the "Company") GeoPharma, Inc. announced today that EdgeWater Research Partners, LLC (http://www.edgewaterresearch.com/) has initiated coverage on the company with a 18-24 month target price of $7.25 and an allocation rating of 4 or Buy.
A copy of the report can be obtained in "For Investors" section of the GeoPharma website at: WWW.GEOPHARMAINC.COM About GeoPharma: GeoPharma, Inc. is a rapidly growing Bio/Pharma company with a diversified business model participating in 3 main market segments: Specialty Pharma, Manufacturing, and Distribution. The Specialty Pharma division specializes in the formulation of generic drugs for human and veterinary usage and the development of medical devices used by oncologists and other medical professionals. The Manufacturing and Distribution divisions, manufacture, package, and distribute generic drugs, nutraceuticals, cosmetics, and functional food products for companies worldwide.
GeoPharma's growth strategy is to capitalize on its research and manufacturing expertise to develop medical devices and high margin generic drug products for niche markets with high barriers to entry. GeoPharma's competitive advantage in these areas is in its ability to navigate the challenges that such market pursuits present effectively.
Currently GeoPharma employs nearly 300 people and operates facilities in Florida, Maryland, Pennsylvania, Nevada, Rhode Island, and Texas utilizing over 330,000 Sq. Ft. of office, warehouse, manufacturing and laboratory facilities.
EdgeWater Research Partners, LLC is an independent micro cap equities research company representing the research of David Lavigne. EdgeWater follows a number of undiscovered small and micro cap stocks through both individual research and its monthly publication, The EdgeWater Micro Monthly. EdgeWater's research is distributed to its subscriber base, and is also available on a piece by piece basis on the Company's website http://www.edgewaterresearch.com/ .
Safe Harbor Statement: This press release may contain statements, which constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including those regarding the company and its subsidiaries' expectations, intentions, strategies and beliefs pertaining to future performance. All statements contained herein are based upon information available to the company's management as of the date hereof, and actual results may vary based upon future events, both within and without management's control. Important factors that could cause such differences are described in the company's periodic filings with the Securities and Exchange Commission. DATASOURCE: GeoPharma, Inc.
CONTACT: Alexander Nachman, Director of Investor and Media Relations of GeoPharma, Inc., +1-727-471-0850, x 243, ; or David Lavigne, President of EdgeWater Research Partners, +1-303-593-2877, Web site: http://www.geopharmainc.com/ http://www.edgewaterresearch.com/
|